{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase, leading to a broader peptide repertoire on MHC-I.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "2. Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccine and anti-PD-L1 combinations improve tumor control in mice.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice",
          "line_ref": "L46"
        },
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        }
      ],
      "caveat": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with better outcomes in human metastatic patients receiving ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    }
  ]
}